As previously reported, Guggenheim analyst Glen Santangelo downgraded Align Technology (ALGN) to Neutral from Buy with a price target of $200, down from $250. Santangelo now believes that competition is more aggressive than he originally anticipated after his proprietary channel checks suggested that the technical and service capabilities of the competition, while still "not nearly as good" as Align, may be evolving faster than expected. Many of the established dental companies - such as Dentsply Sirona (XRAY), 3M (MMM), Envista (NVST) and Henry Schein (HSIC) - are offering clear aligners at discounted prices and making a big push in this area, while the direct-to-consumer model has attracted significant attention in the wake of the recent SmileDirectClub (SDC) IPO, Santangelo stated. In all, his view is that sentiment on Align will likely remain challenged until investors fully understand the impact of the new competitive landscape, which may take until later in 2020.